- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1137EUR$1,250USD£971GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1137EUR$1,250USD£971GBP
- Report
- June 2024
- 200 Pages
Global
From €7233EUR$7,950USD£6,178GBP
- Report
- June 2024
- 200 Pages
Global
From €7233EUR$7,950USD£6,178GBP
- Report
- June 2024
- 260 Pages
Global
From €7233EUR$7,950USD£6,178GBP
- Report
- June 2024
- 200 Pages
Global
From €7233EUR$7,950USD£6,178GBP
- Report
- November 2024
- 173 Pages
Global
From €4231EUR$4,650USD£3,613GBP
- Report
- November 2023
- 171 Pages
Global
From €4231EUR$4,650USD£3,613GBP
- Report
- November 2020
- 260 Pages
Global
From €2502EUR$2,750USD£2,137GBP
- Report
- June 2025
- 400 Pages
Global
From €4503EUR$4,949USD£3,846GBP
- Report
- June 2025
- 200 Pages
Global
From €2537EUR$2,789USD£2,167GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2537EUR$2,789USD£2,167GBP
- Report
- June 2025
- 400 Pages
Global
From €4503EUR$4,949USD£3,846GBP
- Report
- June 2025
- 250 Pages
India
From €2537EUR$2,789USD£2,167GBP
- Report
- April 2023
- 147 Pages
Global
From €4503EUR$4,949USD£3,846GBP
- Report
- June 2025
- 400 Pages
Global
From €4503EUR$4,949USD£3,846GBP
- Report
- February 2024
- 113 Pages
Global
From €4322EUR$4,750USD£3,691GBP
- Report
- June 2026
- 122 Pages
Mexico
From €2729EUR$2,999USD£2,330GBP
€3638EUR$3,999USD£3,107GBP
- Report
- May 2024
- 128 Pages
Global
From €2729EUR$2,999USD£2,330GBP
€3638EUR$3,999USD£3,107GBP
- Report
- May 2024
- 140 Pages
Global
From €2729EUR$2,999USD£2,330GBP
€3638EUR$3,999USD£3,107GBP

Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more